132 related articles for article (PubMed ID: 1499075)
21. [Functional and phenotypic analysis of tumor infiltrating lymphocytes derived from solid tumors and effusion associated lymphocytes in malignant ascites cultured in recombinant interleukin 2].
Itoh K; Shiiba K; Ebina N; Anzai R; Ouchi A; Matsuno S
Nihon Geka Gakkai Zasshi; 1993 Aug; 94(8):781-90. PubMed ID: 8377752
[TBL] [Abstract][Full Text] [Related]
22. Antitumor effects of new-type recombinant interleukin-2.
Feng XS; Zheng XJ; Si QS; Lin YL; Chang Y; Fan PF; Yu JL; Zhang SR; Liu XY
Zhongguo Yao Li Xue Bao; 1992 Sep; 13(5):435-8. PubMed ID: 1300048
[TBL] [Abstract][Full Text] [Related]
23. Solid-phase anti-CD3 antibody activation and cryopreservation of human tumor-infiltrating lymphocytes derived from epithelial ovarian cancer.
Ikarashi H; Aoki Y; Fujita K; Kodama S; Tanaka K
Jpn J Cancer Res; 1992 Dec; 83(12):1359-65. PubMed ID: 1483950
[TBL] [Abstract][Full Text] [Related]
24. Differential in situ expansion and gene expression of CD4+ and CD8+ tumor-infiltrating lymphocytes following adoptive immunotherapy in a murine tumor model system.
Evans R; Duffy TM; Kamdar SJ
Eur J Immunol; 1991 Aug; 21(8):1815-9. PubMed ID: 1907916
[TBL] [Abstract][Full Text] [Related]
25. Improved in vivo efficacy of tumor-infiltrating lymphocytes after restimulation with irradiated tumor cells in vitro.
Burger UL; Chang MP; Nagoshi M; Goedegebuure PS; Eberlein TJ
Ann Surg Oncol; 1996 Nov; 3(6):580-7. PubMed ID: 8915492
[TBL] [Abstract][Full Text] [Related]
26. HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2.
Kooi S; Zhang HZ; Patenia R; Edwards CL; Platsoucas CD; Freedman RS
Cell Immunol; 1996 Dec; 174(2):116-28. PubMed ID: 8954611
[TBL] [Abstract][Full Text] [Related]
27. Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response.
Aebersold P; Hyatt C; Johnson S; Hines K; Korcak L; Sanders M; Lotze M; Topalian S; Yang J; Rosenberg SA
J Natl Cancer Inst; 1991 Jul; 83(13):932-7. PubMed ID: 2067036
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms of adoptive immunotherapy: improved methods for in vivo tracking of tumor-infiltrating lymphocytes and lymphokine-activated killer cells.
Wallace PK; Palmer LD; Perry-Lalley D; Bolton ES; Alexander RB; Horan PK; Yang JC; Muirhead KA
Cancer Res; 1993 May; 53(10 Suppl):2358-67. PubMed ID: 8485722
[TBL] [Abstract][Full Text] [Related]
29. Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies.
Wong JT; Pinto CE; Gifford JD; Kurnick JT; Kradin RL
J Immunol; 1989 Nov; 143(10):3404-11. PubMed ID: 2509557
[TBL] [Abstract][Full Text] [Related]
30. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
Inoue M; Plautz GE; Shu S
Cancer Res; 1996 Oct; 56(20):4702-8. PubMed ID: 8840987
[TBL] [Abstract][Full Text] [Related]
31. In vitro migration of lymphocytes through collagen matrix: arrested locomotion in tumor-infiltrating lymphocytes.
Applegate KG; Balch CM; Pellis NR
Cancer Res; 1990 Nov; 50(22):7153-8. PubMed ID: 2224850
[TBL] [Abstract][Full Text] [Related]
32. Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.
Bouet-Toussaint F; Genetel N; Rioux-Leclercq N; Bansard JY; Levêque J; Guillé F; Patard JJ; Lesimple T; Catros-Quemener V
Eur Cytokine Netw; 2000 Jun; 11(2):217-24. PubMed ID: 10903800
[TBL] [Abstract][Full Text] [Related]
33. Effects of "moxibustion serum" on proliferation and phenotypes of tumor infiltrating lymphocytes.
Chen Y; Zhao C; Chen H; Qin H; Fang F
J Tradit Chin Med; 2003 Sep; 23(3):225-9. PubMed ID: 14535199
[TBL] [Abstract][Full Text] [Related]
34. Characterization of the cytolytic activity of CD4+ and CD8+ tumor-infiltrating lymphocytes in human renal cell carcinoma.
Finke JH; Rayman P; Alexander J; Edinger M; Tubbs RR; Connelly R; Pontes E; Bukowski R
Cancer Res; 1990 Apr; 50(8):2363-70. PubMed ID: 2107973
[TBL] [Abstract][Full Text] [Related]
35. Separation and expansion of tumor infiltrating lymphocytes of digestive system in vitro and their cytotoxicity.
Chen DD; Tan QF; Tao KX
J Tongji Med Univ; 1995; 15(4):220-2, 226. PubMed ID: 8731928
[TBL] [Abstract][Full Text] [Related]
36. [An experimental study of the antitumor activity of tumor-infiltrating lymphocytes (TIL) in human tongue carcinoma in vitro].
Guo W
Zhonghua Kou Qiang Yi Xue Za Zhi; 1992 Sep; 27(5):259-61, 318. PubMed ID: 1306434
[TBL] [Abstract][Full Text] [Related]
37. [Adoptive immunotherapy and metastasized cancer of the kidney. Regulator effects of interleukin-4 on tumor infiltrating lymphocytes (TIL)].
Peyret C; Bochner B; Lee TY; Tso CL; Dekernion JB; Belldegrun A
Chirurgie; 1991; 117(9):700-9. PubMed ID: 1843670
[TBL] [Abstract][Full Text] [Related]
38. Autologous activated lymphocyte therapy in a community hospital.
Horváth J; Szabó-Szabari M; Sinkovics JG
Acta Microbiol Immunol Hung; 1994; 41(2):205-14. PubMed ID: 7804724
[TBL] [Abstract][Full Text] [Related]
39. Clonal dynamics of tumor-infiltrating lymphocytes.
Yu R; Fujio K; Tahara H; Araki Y; Yamamoto K
Eur J Immunol; 2005 Jun; 35(6):1754-63. PubMed ID: 15902685
[TBL] [Abstract][Full Text] [Related]
40. Lymphocytes infiltrating human ovarian tumors: synergy between tumor necrosis factor alpha and interleukin 2 in the generation of CD8+ effectors from tumor-infiltrating lymphocytes.
Wang YL; Si LS; Kanbour A; Herberman RB; Whiteside TL
Cancer Res; 1989 Nov; 49(21):5979-85. PubMed ID: 2507139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
